In vitro activity of SF001: a next-generation polyene versus amphotericin B.

SF001, a next-generation polyene drug, offers broad-spectrum fungicidal activity with less potential for toxicity than classic polyene amphotericin B (AmB). This study compared the in vitro activity of SF001 and amphotericin B against Candida and Aspergillus species. SF001 demonstrated activity comparable to AmB against Candida isolates (MIC50/90 of 0.25/1 and 0.5/0.5 mg/L, respectively). However, Aspergillus isolates exhibited higher susceptibility to SF001 than AmB (MIC50/90 of 0.5/1 and 1/4 mg/L, respectively), notably including AmB-resistant species.